Arcus Biosciences (NYSE:RCUS) Issues Quarterly Earnings Results

Arcus Biosciences (NYSE:RCUS) released its earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.92, Briefing.com reports. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $28.77 million. During the same quarter in the previous year, the firm earned ($1.09) EPS. The company’s revenue was up 480.0% on a year-over-year basis.

Arcus Biosciences Trading Up 3.0 %

Shares of NYSE RCUS traded up $0.49 during midday trading on Friday, reaching $16.64. The company’s stock had a trading volume of 407,413 shares, compared to its average volume of 769,708. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -4.26 and a beta of 0.91. Arcus Biosciences has a one year low of $12.95 and a one year high of $25.47. The company has a 50 day moving average price of $16.95 and a 200 day moving average price of $16.58.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, COO Jennifer Jarrett sold 11,551 shares of Arcus Biosciences stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the sale, the chief operating officer now owns 215,253 shares of the company’s stock, valued at approximately $3,777,690.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, President Juan C. Jaen sold 3,900 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the completion of the sale, the president now owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Jennifer Jarrett sold 11,551 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total value of $202,720.05. Following the completion of the sale, the chief operating officer now directly owns 215,253 shares in the company, valued at approximately $3,777,690.15. The disclosure for this sale can be found here. Insiders sold 53,455 shares of company stock worth $1,014,779 in the last quarter. 12.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

RCUS has been the subject of several research reports. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Arcus Biosciences in a research report on Thursday. Mizuho lowered their price objective on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, January 30th. Finally, Truist Financial restated a “buy” rating and issued a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.25.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.